Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.
Twice Daily Poziotinib Beats Safety of Single Dose in NSCLC
April 5th 2021Perliminary analyses of 2 cohorts from the phase 2 multicohort ZENITH20 trial evaluating poziotinib show clinical activity and tolerability for the tyrosine kinase inhibitor in patients with non–small cell lung cancer harboring EGFR and HER2 exon 20 insertions.
Expanding Molecular Testing Leads to Personalized Care in GI Cancer
March 29th 2021A key advance in treating patients with gastrointestinal cancer is molecular profiling of the tumor that results in specific targets being identified. The standard of care for GI cancer has consisted of surgery, radiotherapy, and chemotherapy, but these standards have had limited efficacy and considerable toxicity that impact patients’ quality of life.
Apatinib/Doxorubicin Combination Improves PFS Over Single Agent in Ovarian Cancer
March 21st 2021The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.
PD-1/PARP Triplet Regimen Shows Positive Clinical Activity, Tolerability in Ovarian Cancer
March 20th 2021The addition of the investigational anti–PD-1 immunotherapy agent, dostarlimab, to niraparib and bevacizumab demonstrated positive antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.
Nab-Paclitaxel Demonstrates Noninferiority to Docetaxel in Previously Treated Patients With NSCLC
January 29th 2021Progression-free survival and overall survival benefits, combined with a higher objective response rate, confirmed the noninferiority of nab-paclitaxel compared with docetaxel in previously treated patients with advanced non–small cell lung cancer, according to phase 3 trial results.
Positive Findings From ADAURA Trial Reported, But Questions Remain
December 29th 2020The early unblinding of results from the phase 3 ADAURA clinical trial evaluating osimertinib, a third-generation EGFR tyrosine kinase inhibitor, was met with much fanfare in the oncology community as details of the interim results spread.
Omission of Postoperative Radiotherapy Has No Effect on Metastatic Risk in Low-Grade Breast Cancer
December 10th 2020The use of whole breast irradiation can be omitted in patients 65 years and older with pT1-2 tumors on local control at 10 years after breast-conserving surgery and adjuvant endocrine therapy in low risk, older patients.
Enriched CAR T-Cell bb21217 Improves Response and Duration in Patients With Multiple Myeloma
December 5th 2020Enriching the CAR molecule bb2121 with the PI3K inhibitor bb007 improved response and extended duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.
Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022
December 1st 2020The MET inhibitor TPX-0022 was safe and well tolerated in a phase 1 dose-escalation study, SHIELD-1, involving patients with advanced solid tumors harboring MET alterations, according to results presented during the 32nd Molecular Targets and Cancer Therapeutics Symposium.
Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer
November 15th 2020Patients who received palbociclib and fulvestrant before chemotherapy for metastatic breast cancer had greater clinical benefit versus patients who received placebo and fulvestrant, according to an exploratory subgroup analysis of the phase 3 PALOMA-3 trial.
Safety, Tolerability Profile for Low-Dose Lenvatinib Is Similar to Standard Dose in RCC
November 7th 2020Findings from a phase 2 trial evaluating lenvatinib given at 2 different starting doses, 14 mg versus 18 mg, in combination with everolimus, suggest the lower dose is similar to the standard dose in terms of efficacy and safety with minimal differences observed between the 2 arms.
TNBC Heterogeneity Opens Door for Emerging Targeted Therapies
October 26th 2020As a greater understanding of triple-negative breast cancer heterogeneity develops over time, combinations of PD-1/PD-L1 plus PARP inhibitors, androgen receptor targeted agents, and PI3K/AKT/mTOR pathway inhibitors are undergoing evaluation by investigators in the field.
Preliminary Safety and Efficacy Results Observed for AMG 160 in mCRPC
October 23rd 2020The bispecific T‐cell engager, AMG 160, demonstrated a manageable safety profile and preliminary evidence of efficacy in heavily pretreated patients with metastatic castration-resistant prostate cancer in a 2-part, phase 1 open-label study.